14 terminated. 14 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 14 | Terminated 14 |
| Phase 2 | 1 | Terminated 1 |
Follow Osteoporosis: new trials by email Literature Review of Osteoporosis trials Research Report on Osteoporosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Averting Complications of Proton Pump Inhibitor Therapy by Effervescent Calcium Magnesium Citrate EffCaMgCit, Placebo - Osteoporosis, Hypomagnesemia | Phase 3 | Terminated | University of Texas Southwestern Medical Center | 62 | 2019-01-01 | 2022-08-17 |
| Denosumab Versus Zoledronic Acid in Thalassemia-Induced Osteoporosis Denosumab 60 MG/ML Prefilled Syringe, Zoledronic Acid 5Mg/Bag 100Ml Inj - Thalassemia Majors (Beta-Thalassemia Major), Osteoporosis | Phase 3 | Terminated | Hamad Medical Corporation | 17 | 2018-05-14 | 2019-12-12 |
| Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Oral Bisphosphonate (MK-0822-076) odanacatib, placebo to odanacatib - Osteoporosis | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 135 | 2013-03-14 | 2019-09-04 |
| Comparison of the Effect of an Ongoing Treatment With Alendronate or a Drug Holiday on the Fracture Risk in Osteoporotic Patients With Bisphosphonate Long Term Therapy Alendronate, Placebo - Osteoporosis | Phase 3 | Terminated | Evangelisches Krankenhaus Lutherhaus gGmbH | 436 | 2012-02-01 | 2019-02-12 |
| FES-Rowing Versus Zoledronic Acid to Improve Bone Health in Spinal Cord Injury (SCI) FES-Rowing, Zoledronic acid - Osteoporosis | Phase 2 / Phase 3 | Terminated | Antonio Lazzari | 70 | 2011-02-01 | 2016-04-11 |
| Zoledronic Acid in MS-patients With Osteoporosis Zoledronic Acid, Placebo, Calcium and Vitamin D combination - Osteoporosis, Multiple Sclerosis | Phase 3 | Terminated | Novartis | 29 | 2010-10-01 | 2013-11-26 |
| Use of Oral Bisphosphonates in the Treatment of Osteoporosis of Non-walking Children With Cerebral Palsy FOSAMAX, PLACEBO - Osteoporosis, Cerebral Palsy | Phase 3 | Terminated | Department of Clinical Research and Innovation | 2 | 2009-02-01 | 2012-03-26 |
| A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018) Odanacatib, Placebo for Odanacatib, Vitamin D3 - Postmenopausal Osteoporosis | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 16071 | 2007-09-13 | 2024-06-11 |
| Effect of Exercise on Risk-factors of Elderly Women physical exercise, wellness - Atrophy | Phase 3 | Terminated | University of Erlangen-Nürnberg Medical School | 246 | 2006-01-01 | 2015-06-01 |
| Cancer and Osteoporosis Research With Alendronate and Lupron (C.O.R.A.L ) Alendronate - Osteoporosis | Phase 3 | Terminated | Canadian Urology Research Consortium | 182 | 2005-07-01 | 2009-08-12 |
| Fingernails in Evaluating Bone Health in Postmenopausal Women With Breast Cancer Undergoing Hormone Therapy on Clinical Trial IBCSG-1-98 spectroscopy - Breast Cancer, Osteoporosis | Phase 3 | Terminated | ETOP IBCSG Partners Foundation | 60 | 2005-04-01 | 2012-07-27 |
| Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation cholecalciferol, calcium gluconate, zoledronic acid - Osteoporosis, Prostate Cancer | Phase 3 | Terminated | Northwestern University | 53 | 2003-03-01 | 2020-12-08 |
| Low-Dose Hormone Replacement Therapy and Alendronate for Osteoporosis Alendronate, Estrogen/progestin therapy - Osteopenia, Osteoporosis | Phase 3 | Terminated | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 240 | 1999-10-01 | 2007-01-04 |
| Safety of Estrogens in Lupus: Hormone Replacement Therapy Premarin and Provera - Systemic Lupus Erythematosus | Phase 3 | Terminated | NYU Langone Health | 350 | 1996-04-01 | 2013-05-03 |
Atrophy (1) · Bone Diseases, Metabolic (1) · Breast Neoplasms (1) · Cardiovascular Diseases (1) · Cerebral Palsy (1) · Diabetes Mellitus (1) · Lupus Erythematosus, Systemic (1) · Motor Activity (1) · Multiple Sclerosis (1) · Osteoporosis, Postmenopausal (1) · Osteoporotic Fractures (1) · Prostatic Neoplasms (1) · beta-Thalassemia (1)
Bone Diseases (14) · Metabolic Diseases (14) · Musculoskeletal Diseases (14) · Nutritional and Metabolic Diseases (14) · Bone Diseases, Metabolic (13) · Autoimmune Diseases (2) · Immune System Diseases (2) · Neoplasms (2) · Neoplasms by Site (2) · Nervous System Diseases (2) · Skin and Connective Tissue Diseases (2) · Anemia (1) · Anemia, Hemolytic (1) · Anemia, Hemolytic, Congenital (1) · Autoimmune Diseases of the Nervous System (1)
Alendronate (4) · Zoledronic Acid (4) · Cholecalciferol (2) · odanacatib (2) · Calcium (1) · Calcium Carbonate (1) · Calcium Gluconate (1) · Denosumab (1) · Estrogens (1) · Estrogens, Conjugated (USP) (1) · Exercise (1) · Health (1) · Medroxyprogesterone Acetate (1) · Spectrum Analysis (1) · effervescent calcium magnesium citrate (1)
Merck Sharp & Dohme LLC (2) · Antonio Lazzari (1) · Canadian Urology Research Consortium (1) · Department of Clinical Research and Innovation (1) · ETOP IBCSG Partners Foundation (1) · Evangelisches Krankenhaus Lutherhaus gGmbH (1) · Hamad Medical Corporation (1) · NYU Langone Health (1) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (1) · Northwestern University (1) · Novartis (1) · University of Erlangen-Nürnberg Medical School (1) · University of Texas Southwestern Medical Center (1)
United States (5) · Germany (3) · France (1) · Qatar (1)
Antonio A Lazzari, MD (1) · Charles L. Bennett, MD, PhD (1) · Jill Buyon, M.D. (1) · Joan M. Lappe, PhD, RN (1) · Johannes Pfeilschifter, Prof. Dr. med. (1) · Khashayar Sakhaee, MD (1) · Lesley Carr, M.D. (1) · Leslie Morse, DO (1) · Mark Towler, MD (1) · Michelle Petri, M.D. (1) · Mohamed Yassin (1) · Robert R. Recker, MD (1)
PMID 15968009, PMID 20101013, PMID 20171529, PMID 31676222, PMID 32119749, PMID 33724542, PMID 35711006
2009 (1), U01AR042540 (1)